Navigation Links
Mylan Launches Generic Version of Viramune® Tablets
Date:5/23/2012

PITTSBURGH, May 23, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nevirapine Tablets USP, 200 mg. This product is the generic version of Boehringer Ingelheim's Viramune® and is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection. (1)

Mylan CEO Heather Bresch said: "The launch of Nevirapine Tablets, 200 mg, in the U.S. further expands the reach of Mylan's global ARV portfolio. Currently, approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and the company is committed to continue bringing affordable, high quality generic ARVs to market in the U.S."

Nevirapine Tablets, 200 mg, had U.S. sales of approximately $116.6 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping its product immediately.

Currently, Mylan has 173 ANDAs pending FDA approval representing $92 billion in annual sales, according to IMS Health. Thirty-eight of these pending ANDAs are potential first-to-file opportunities, representing $25.5 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com  

(1) Both fatal and non-fatal liver damage and skin reactions have been reported in patients taking Nevirapine. Patients must be closely monitored during the first 18 weeks of therapy to detect these conditions.

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
2. Mylan Launches Generic Version of Plavix® Tablets
3. Mylan Launches Generic Lipitor® in Five European Countries
4. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
5. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
6. Mylan Launches Generic Version of Zyprexa® Tablets
7. Mylan Launches First Generic Version of Lescol® Capsules
8. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
9. Mylan One of First to Launch Generic Version of Boniva®
10. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
11. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/31/2017)... July 31, 2017 7D Surgical, developer of ground ... purchased the 7D Surgical System to support its strategic sales ... D.C. and Virginia.  7D Surgical has entered into ... of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Greenfield Advisors is honored to be ... for the second year in a row. The Inc. 5000 list honors private businesses ... “To be on the list once is a great accomplishment, but for us to ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & Durrett, ... in business this year, and they’re marking the milestone by undertaking a significant ... patients. , It stands to reason that, given the central importance of ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... has received a three-year grant totaling $975,000, renewing its funding from the Health ... Human Services. , This funding marks, the fourth time the HRSA administration has ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Endoscopes states: “Drying the endoscope after every reprocessing cycle, both between patient procedures ... transmission and nosocomial infections. Drying is as important to the prevention of disease ...
(Date:8/16/2017)... Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... spot on the Inc 5000 list for the fourth consecutive year. With ... Inc. 5000 2017 list of the nation’s fastest growing companies. , Previous ...
Breaking Medicine News(10 mins):